Innovative Product Portfolio Iconovo's proprietary dry powder inhalers and inhouse formulation capabilities offer significant opportunities to partner with pharmaceutical companies seeking to develop or commercialize inhalation-based therapies, especially in areas like biologics and new drug delivery platforms.

Strategic Collaborations Recent partnership with Lonza Group to develop intranasal biologic formulations highlights Iconovo's potential as a collaborator for companies exploring advanced drug delivery methods, opening avenues for joint product development and shared market entry strategies.

Recognition & Awards Being awarded the Best Inhalation Therapy Company 2024 by EU Business News enhances credibility and visibility among potential clients and investors, positioning Iconovo as a leading innovator in inhalation technology and increasing sales opportunities.

Market Expansion Efforts Recent grants for market efforts in South Korea and ongoing studies on inhalable oxytocin present opportunities to engage with healthcare providers and pharmaceutical companies in emerging markets seeking novel inhalation treatments.

Growing R&D Focus Iconovo’s active development of new inhalation therapies, including improved nasal inhalers and biologic formulations, indicates an expanding product pipeline ideal for OEM partnerships, licensing agreements, or distribution collaborations to accelerate market access.